Current treatments

Current treatments


Today, nonsurgical therapies are typically considered for men with early-phase disease (ie, <12 months’ duration) characterized by unstable or progressive deformity and painful erections, as well as those who are not psychologically ready for or interested in surgery.1

 

 

Video parts

Oral treatments
 
Traction therapy
 
Intralesional treatments and Xiapex
 
Surgery
 
The psychological impact of Peyronie’s disease

 


 

 

Non-surgical treatments

NOTE

Some of the various nonsurgical treatment interventions that have been used are listed below. Although many nonsurgical options are used in clinical practice, Xiapex is the only EMA-approved medicine for the treatment of Peyronie’s disease.2 Read more about Xiapex.

 

Nonsurgical Interventions1,3

Oral and topical treatments

  • Vitamin E
  • Pentoxifylline
  • L-arginine Potassium aminobenzoate (Potaba)*
  • Tamoxifen
  • Colchicine
  • Ubiquinone

Intralesional injections

  • Corticosteroids
  • Verapamil
  • Interferon

Devices

  • Penile traction devices
  • Vacuum erection devices


* Potaba is approved in Germany and England. None of the other interventions are approved in any European country for Peyronie’s Disease.

Surgical treatments

Surgery is an option for severe curvature abnormality and/or treatment resistant erectile dysfunction in the stable phase of disease. It is often reserved for the most severe cases due to the potential risk of complications, including penile shortening, glans numbness, neurovascular injury, infection and erectile dysfunction.4-6 Surgery aims to correct curvature and allow satisfactory intercourse. Reports vary however, in terms of:
– Reduction of curvature deformity3
– Side effects, such as penile shortening and erectile dysfunction3

 

References:

  1. Ralph D et al. J Sex Med. 2010;7(7):2359-2374.
  2. Xiapex Summary of Product Characteristics.
  3. Hatzimouratidis K et al, European Urology 62 (2012) 543–552.
  4. Taylor FL and Levine LA. Urol Clin N Am 34 (2007) 517–534.
  5. Chung E et al. J Sex Med 2011;8:594–600.
  6. Benson J et al. Current Urology Reports 2009, 10:468–474.